Vice President, Gene Editing Core
Intellia Therapeutics
About this role
The Vice President, Gene Editing Core leads a cross‑functional team that applies cutting‑edge genomics and molecular biology tools to advance genome‑editing therapies. This senior leader oversees project planning, execution, assay development, and collaboration across R&D functions to drive innovative gene‑editing solutions.
Skills
Qualifications
About Intellia Therapeutics
intelliatx.comIntellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
Recent company news
Intellia TherapeuticsIntellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
1 week ago
Seeking AlphaIntellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory (NASDAQ:NTLA)
3 days ago
Yahoo FinanceIntellia Therapeutics, Inc. (NTLA): A Bull Case Theory
2 weeks ago
Intellia TherapeuticsIntellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
2 weeks ago
GlobeNewswireIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 days ago
About Intellia Therapeutics
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Leadership Team
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
Unlock Company Insights
View leadership team, funding history,
and employee contacts for Intellia Therapeutics.
Salary
$327k – $400k
per year
More jobs at Intellia Therapeutics
Similar Jobs
Co-op: Off-Target Analysis of Gene Editing
Prime Medicine
Senior Scientist, Cell and Molecular Biology, Gene Editing
Editas Medicine
Scientist II, Computational Biology & AI
CRISPR Therapeutics
Vice President, Assay Development
Stellaromics Inc
Researcher for Center for Advanced Genome Engineering
St. Jude
Vertex Fall Co-op 2026, Gene Editing Research
Vertex